Last reviewed · How we verify

NCT07364838

Study to Evaluate the Effect of Food on the Pharmacokinetics and Pharmacodynamics Characteristics in Healthy Adult Volunteers

Completed Phase 1 Last updated 23 January 2026
What this trial tests

Phase 1 trial testing DW4421 in GERD (Gastroesophageal Reflux Disease) in 24 participants. Completed in 8 April 2025.

Timeline
21 November 2024
Primary endpoint
8 April 2025
8 April 2025

Quick facts

Lead sponsorDaewon Pharmaceutical Co., Ltd.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment24
Start date21 November 2024
Primary completion8 April 2025
Estimated completion8 April 2025
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Daewon Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 19 to 50, any sex, with GERD (Gastroesophageal Reflux Disease). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Randomized, Open-label, Oral in healthy volunteers

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of DW4421

Trials testing the same drug.

Other recruiting trials for GERD (Gastroesophageal Reflux Disease)

Currently open trials in the same condition.

Other Daewon Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07364838.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing